Should You Invest in the First Trust Materials AlphaDEX ETF (FXZ)?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 17 2024
0mins
Source: NASDAQ.COM
ETF Overview: The First Trust Materials AlphaDEX ETF (FXZ), launched in 2007, provides broad exposure to the Materials sector with assets over $335 million and an expense ratio of 0.62%. It aims to match the performance of the StrataQuant Materials Index and has a current Zacks ETF Rank of 3 (Hold).
Performance Insights: FXZ has experienced a -6.77% loss year-to-date and a 0.83% gain over the past year, with a beta of 1.19 indicating medium risk. Its top holdings include United States Steel Corporation, FMC Corporation, and Reliance Inc., which collectively account for about 45.74% of total assets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FMC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FMC
Wall Street analysts forecast FMC stock price to rise
14 Analyst Rating
3 Buy
10 Hold
1 Sell
Hold
Current: 10.950
Low
13.00
Averages
19.08
High
28.00
Current: 10.950
Low
13.00
Averages
19.08
High
28.00
About FMC
FMC Corporation is a global agricultural sciences company engaged in providing farmers solutions that increase the productivity and resilience of their land. The Company’s crop protection solutions, including biologicals, crop nutrition, digital and precision agriculture, enable growers and crop advisers to address their challenges economically while protecting the environment. Its portfolio consists of three major pesticide categories: insecticides, herbicides and fungicides. The majority of its product lines consist of insecticides and herbicides, and it has a portfolio of fungicides mainly used in high-value crop segments. Its insecticides are used to control a wide spectrum of pests, while its herbicide portfolio primarily targets a large variety of difficult-to-control weeds. In addition, it is also investing in its Plant Health program, which includes biologicals, crop nutrition, and seed treatment products. Biological technologies serve as complements to its synthetic products.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Strategic Investment Agreement: FMC and Tessenderlo Group have entered into a definitive agreement where Tessenderlo will make a strategic minority equity investment of approximately $400M at $13.30 per share, resulting in Tessenderlo owning about 20% of FMC's outstanding shares, marking the conclusion of FMC's Board's exploration of strategic options.
- Debt Repayment Plan: FMC intends to utilize the investment funds to pay down debt, aiming to achieve a target of approximately $1B in debt reduction, thereby improving the company's financial health and enhancing future financial flexibility.
- Stock Price Reaction: FMC shares rose by 2% in after-hours trading, reflecting a positive market response to the investment agreement, which may bolster investor confidence in the company's future growth potential.
- Strategic Implications: This investment not only provides FMC with essential funding but also signifies Tessenderlo's confidence in FMC's future, potentially laying the groundwork for enhanced competitiveness and market expansion for FMC in the industry.
See More
- Strategic Investment Agreement: FMC Corp. has announced a definitive agreement with Tessenderlo Group for a strategic minority equity investment of approximately $400 million, with Tessenderlo acquiring shares at $13.30 each, resulting in a 20% ownership stake in FMC, thereby enhancing its influence within the company.
- Debt Reduction Plan: FMC intends to utilize the proceeds from this investment to reduce its debt, which is expected to assist in achieving its target of approximately $1 billion in debt repayment, thereby improving the company's financial health and enhancing operational flexibility for future growth.
- Conclusion of Strategic Review: This transaction concludes the strategic alternatives review initiated by FMC in February 2026, indicating that the company will continue to operate independently and execute its strategic plan, ensuring long-term sustainability and growth.
- Stock Price Reaction: Following the announcement, FMC's stock price rose by 0.35% to $11.50 on the New York Stock Exchange, with an additional 4% increase in after-hours trading to $11.96, reflecting a positive market response to the investment news.
See More
- Investment Amount: Tessenderlo Group will invest approximately $400 million in FMC at $13.30 per share, resulting in Tessenderlo owning about 20% of FMC shares post-transaction, reflecting strong confidence in FMC's growth potential.
- Strategic Alignment: Tessenderlo CEO Luc Tack stated that this investment perfectly aligns with their strategy to expand their agro platform through cornerstone investments, indicating a long-term commitment to high-quality companies that may drive FMC's further development in agricultural sciences.
- Debt Repayment Plan: FMC intends to use the funds from this transaction to repay debt, aiming to achieve its target of around $1 billion in debt reduction, which will improve the company's financial health and enhance its market competitiveness.
- Conclusion of Strategic Options: This transaction marks the conclusion of FMC's search for strategic options announced in February, indicating that the company has solidified its future direction and aims to strengthen its capital structure by bringing in strategic investors.
See More
- Strategic Investment Amount: Tessenderlo Group will invest approximately $400 million in FMC at a price of $13.30 per share, resulting in a 20% ownership stake in FMC, significantly enhancing FMC's capital structure and supporting future growth.
- Debt Paydown Target: FMC plans to utilize the investment funds to pay down approximately $1 billion in debt, improving financial flexibility and providing funding assurance for independent operations and the advancement of its R&D pipeline.
- Completion of Strategic Review: This transaction marks the conclusion of FMC's Board of Directors' exploration of strategic options, demonstrating the company's commitment to optimizing its capital structure and focusing on core business, which is expected to create long-term value for shareholders.
- Positive Market Reaction: FMC's CEO stated that this investment will bring significant growth potential to the company, and combined with recent capital operations, FMC's leverage and liquidity have improved significantly, which is expected to enhance its competitive position in the market.
See More
- Property Sale Agreement: FMC Corp. has entered into a framework agreement to sell its Newark, Delaware property for approximately $114 million, with the transaction expected to close in Q4 2026, reflecting the company's proactive asset management strategy.
- Leaseback Arrangement: Following the sale, FMC intends to lease back the facilities it operates under a separate lease agreement, ensuring continuity in its research operations while maintaining business stability amid asset changes.
- R&D Center Continuity: FMC's Stine Research Center, its global R&D headquarters, will continue to operate at the site post-transaction, a decision aimed at minimizing disruption to the company's research activities and ensuring ongoing innovation capabilities.
- Adjacent Property Retention: FMC will retain ownership of its adjacent Maryland properties, further solidifying its business foundation in the region and demonstrating the company's ongoing commitment to future growth and market demands.
See More
- Asset Sale Announcement: FMC Corporation has announced the sale of its Newark, Delaware property for approximately $114 million, aimed at optimizing its asset base and reducing debt to strengthen financial stability.
- Leaseback Agreement: Following the sale, FMC intends to lease back the facilities it operates, ensuring that its global R&D headquarters, the Stine Research Center, continues to function without disruption, thereby maintaining its core research capabilities.
- Strategic Optimization Focus: This transaction reflects FMC's commitment to reducing underutilized real estate, with proceeds directed towards debt reduction while preserving investments in future growth and R&D capabilities.
- Transaction Timeline: The deal is expected to close in the fourth quarter of 2026, subject to due diligence and other closing conditions, with potential renegotiation of terms during the diligence period.
See More









